Telomerase activity is involved in telomere length maintenance. Leukocytes, unlike many human somatic tissues, have detectable telomerase activity. These cells provide a normal human cell type in which to study telomerase. We studied the regulation of telomerase activity and the telomerase RNA component as leukocytes were stimulated to enter the cell cycle. In primary human leukocytes stimulated with phytohemagglutinin, telomerase activity increased >10-fold as naturally quiescent cells entered the cell cycle. Antibodies to the T cell receptor (TCR)/CD3 complex and the costimulatory CD28 receptor induced telomerase activity in a T cell-enriched population of cells. Rapamycin, an immunosuppressant that blocks TCR/CD3 signal transduction pathways and cdk2 activation, blocked telomerase induction. Hydroxyurea, an inhibitor of S phase, did not block cdk2 kinase activity or telomerase activation. In summary, telomerase is regulated in Gi phase as normal human T cells enter the cell cycle.
INTRODUCTION
In mammals, cell-cycle progression is often regulated by external signals that are transmitted to a cell through a variety of well-defined signal transduction pathways. Understanding the processes that are regulated by the external signals provides valuable insight into the regulation of cell proliferation. Telomerase activity is tightly regulated during mammalian development and may be required for the long-term proliferation of some cell types. To begin to understand the pathways that regulate telomerase in normal human cells, we studied telomerase activity during human T cell activation.
Telomerase is a ribonucleoprotein DNA polymerase that synthesizes telomere repeats onto chromosome ends Blackburn, 1985,1987; Morin, 1989; Prowse et al., 1993) . In most eukaryotes telomere DNA consists of many tandem repeats of simple sequence motifs; for example, human telomeres contain -10 kilobase pairs (kbp) of tandem TTAGGG repeats (reviewed in Henderson, 1995) . The addition of telomere sequence repeats by telomerase balances telomere shortening that occurs with each cell division, presum-but is specifically down-regulated during postnatal growth (Blasco et al., 1995) . Although many adult human somatic tissues do not express telomerase, some adult tissues, such as lymphocytes, do express active enzyme (Broccoli et al., 1995; Counter et al., 1995; Hiyama et al., 1995) .
Telomerase activity is present in many human tumors and immortal cell lines (reviewed in Harley et al., 1994; Kim et al., 1994; Bacchetti and Counter, 1995) . Evidence from cultured cell lines suggests that telomerase activation may be required for the indefinite proliferation of immortal cancer cells (Counter et al., 1992 (Counter et al., , 1994 Shay et al., 1993) . Thus, telomerase inhibitors have been proposed as potential anticancer agents (reviewed in Harley et al., 1994; Bacchetti and Counter, 1995) .
Telomere shortening with aging is observed in a variety of human cell types, including white blood cells ; reviewed in Harley, 1995a; Hastie et al., 1990; Lindsey et al., 1991; Vaziri et al., 1993) . In addition to total leukocyte populations, telomere shortening is seen in hematoroietic progenitor cells (Vaziri et al., 1994) and in CD4 naive and memory cells (Weng et al., 1995) . In the CD4+ T cells, the naive cells have longer telomeres than the memory T cells, and long telomeres correlated with a higher replicative capacity in culture (Weng et al., 1995) .
Although normal leukocytes express telomerase activity (Broccoli et al., 1995; Counter et al., 1995; Hiyama et al., 1995) , telomere length shortens in leukocytes in vivo (Vaziri et al., 1993) . Telomere shortening during human aging has also been observed in hematopoietic progenitor cells (CD34+, CD38-/lo) that express telomerase (Vaziri et al., 1994; Hiyama et al., 1995) . Either the telomerase that is present in these cells is insufficient to maintain telomeres, or some additional essential component of telomere length maintenance is absent in these cells.
Although the identification of telomerase activity in normal leukocytes raises new considerations for antitelomerase cancer therapies, it also provides an opportunity to study telomerase regulation in a noncancerous cell type. Signal transduction pathways that regulate leukocyte development and proliferation are well established. Unstimulated leukocytes isolated directly from human blood are arrested in the GO phase of the cell cycle (reviewed in Crabtree, 1989; Ullman et al., 1990) . Cross-linking of cell surface receptors on T cells by lectins or antibodies initiates a signal transduction cascade that alters gene expression and leads to entry into the cell cycle and DNA synthesis (Ullman et al., 1990; Crabtree and Clipstone, 1994) . To begin to understand telomerase regulation in normal human cells, we analyzed telomerase activity and the telomerase RNA component in T cells stimulated to enter the cell cycle.
MATERIALS AND METHODS

Isolation and Culturing of Leukocytes
Peripheral blood leukocytes were isolated from heparin-treated blood by density gradient centrifugation in Ficoll and sodium diatrizoate solution (Lymphocyte Separation Medium; Boehringer Mannheim, Indianapolis, IN). Whole blood was layered on the Ficoll solution and centrifuged for 20 min at 1800 rpm. The gradient interface, containing peripheral blood mononuclear cells, was collected, and the cells were washed in phosphate-buffered saline (PBS). The percentage of CD2+ cells (T cells) and CD20+ cells (B cells) was determined by cell surface staining and flow cytometry with anti-CD2 antibodies (clone RPA-2.10; Pharmingen, San Diego, CA) and CD20 antibodies (clone 2H7; Pharmingen). The leukocytes were typically cultured at 5-10 x 105/ml in RPMI media (Life Technologies, Gaithersburg, MD) supplemented with 2 mM glutamine and 20% fetal bovine serum (FBS; HyClone, Logan, UT). For the stimulation/depletion/restimulation experiment, the leukocytes were cultured at 5 x 106 cells/ml from day 0 to day 3. At the time of addition of the IL-2, the cells were diluted 10-fold in serumcontaining media.
Stimulation and Inhibition of Leukocyte Proliferation
Phytohemagglutinin (M form; Life Technologies) and interleukin 2 (Lymphocult-T; Biotest, Denville, NJ) were prepared according to the manufacturer's instructions. Interleukin 2 was added to the culture medium at a final concentration of 20 U/ml. Rapamycin (kind gift of the Drug Synthesis and Chemistry Branch, Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, Bethesda, MD) was dissolved in 100% ethanol and added to the medium at a final concentration of 0.05-500 nM. Hydroxyurea (Sigma Chemical, St. Louis, MO), dissolved in sterile distilled water, was added to the medium at a final concentration of 10 mM.
Enrichment for Quiescent T Cells and CD3 and CD28 Stimulation A leukocyte fraction enriched for quiescent T cells was prepared as described . Peripheral blood leukocytes from a Ficoll gradient interface were washed with PBS, pelleted, resuspended in 1 ml of 150 mM NaCl and 30% Percoll (Pharmacia, Piscataway, NJ) solution, and layered onto a discontinuous Percoll gradient. The gradient contained 2.5 ml of each of the following Percoll solutions (bottom to top): 60, 55, 50, 45, and 40%. Colored density beads (Pharmacia) were included in an adjacent gradient as density markers. After centrifugation at 1500 x g for 20 min, the dense fraction (including the 55%/60% Percoll interface and 1.5 ml of the 60% fraction) was removed and diluted to <15% Percoll in PBS. To deplete B cells, the cells were pelleted, resuspended in RPMI + 20% FBS, and loaded onto a sterile, nylon wool column in one void volume. After incubation for 1 h at 37°C, the nonadherent cells were collected by washing the column with several void volumes of media. Cell number was determined at each step of purification. From 50 ml of whole blood, 5 x 107 cells were obtained from the Ficoll interface, 3.3 x 106 cells from the dense fraction of the Percoll gradient, and 1.5 x 106 cells from the nylon wool column. The cells were pelleted, resuspended in media, and cultured in the presence of anti-CD3 and anti-CD28 antibodies. The anti-CD3 antibodies (OKT3 ascites; kind gift of Dr. Dafna Bar Sagi, State University of New York, Stony Brook) were diluted 1:10 in PBS and used to coat the wells of a 96-well tissue culture plate by incubation at 37°C for 1 h, followed by washing with PBS. Anti-CD28 antibodies were added to the media at a final concentration of 10 ng/ml. Kim et al., 1994) . The modified telomerase assay was performed as follows: 5 ,ul of cellular extract was mixed with 5 ,l of a 2x telomerase reaction mix containing (in mM) 100 Tris acetate, pH 8.5, 100 potassium acetate, 6 MgCl2, 2 spermine, 2 EGTA, 10 ,B-mercaptoethanol, 4 thymidine triphosphate (dTTP), 4 dATP, 4 2-deoxyguanosine-5'-triphosphate (dGTP), and 2 unlabeled telomerase substrate (TS) oligonucleotide (Kim et al., 1994 [Kim et al., 1994 ; N. Kim, personal communication] (BSA) . Probes for the human telomerase RNA and 5S RNA were added simultaneously to the prehybridization mixture. The human telomerase RNA (hTR) antisense riboprobe was generated by in vitro transcription of the hTR gene cloned behind the SP6 promoter in the pGEM-5Zf vector. The specific activity of the hTR probe was 1.6 x 105 cpm/fmol. The 5S RNA probe was generated by random hexamer labeling of a 170 bp PCR fragment encompassing the 5S gene (PCR primers 5'GCACG-GCCGGCCGGGCTG3' and 5'AAGCCTACAGCACCCGG3'). The specific activity of the 5S RNA probe was 5 x 104 cpm/fmol.
Immunoprecipitation, Kinase Assay, and Western
For immunoprecipitations and immunoblotting, the cells were lysed in NP40 buffer (50 mM HEPES, pH 7.0, 50 mM NaCl, 0.1% NP40, 1 mM phenylmethylsulfonyl fluoride, 1 ,ug/ml leupeptin, 1 ,tg/ml pepstatin, and 5 mM dithiothreitol), and insoluble debris was removed by centrifugation at 14,000 x g for 10 min. For immunoprecipitation and kinase assays, the lysates were used immediately and were not frozen, because this results in decreased kinase activity. Before immunoblotting, lysates were stored at -80°C. Immunoprecipitations and immunoblotting were performed as described in Buchkovich and Ziff (1994) . For immunoprecipitations, extracts containing 70 Ag of total protein, as determined by Bio-Rad Protein Concentration Assay, were used. Anti-Cdk2 polyclonal antibody (5 ,ug; Upstate Biotechnology, Lake Placid, NY) or polyclonal rabbit anti-mouse antibody (Upstate Biotechnology) was added to each sample. For immunoblotting, extracts containing 50 ,ug of protein were loaded. The same blot was probed with 2 Ag/ml anti-cdk2 polyclonal antibody (Upstate Biotechnology), 2 ,tg/ml anti-cyclin E (clone HE12; Pharmingen), and 1:1000 dilution of anti-p27Kip1 antisera (kind gift of Hui Zhang, Cold Spring Harbor Laboratory, NY), followed by HRP-conjugated goat anti-rabbit (Sigma) or HRP-conjugated rabbit anti-mouse (Cappel). The HRP activity was detected by an enhanced chemiluminescent substrate system (SuperSignal; Pierce Chemical, Rockford, IL). The blot was stripped of antibodies for sequential probing by incubation in 2% SDS, 62.5 mM Tris, pH 6.8, and 100 mM 13-mercaptoethanol for 20 min at 65°C.
For kinase assays, immune complexes were washed with kinase buffer containing (in mM) 20 Tris, pH 7.5, 30 NaCl, 10 MgCl2, and 1.0 dithiothreitol and then incubated in a 50 ,ul reaction containing kinase buffer (1 x), 20 ,uM ATP, 5 ,uCi y-32P-ATP (6000 Ci per mmol), and 50 ,ug/ml histone HI (Boehringer Mannheim). The reactions were stopped by the addition of 2 x Laemmli sample buffer. Histone HI was separated from free y-32P-ATP on 10% polyacrylamide gel.
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The leukocytes were treated with PHA, which binds to the TCR/CD3 complex on T cells (Kanellopoulos et al., 1985) . In a mixed leukocyte population from peripheral blood, PHA stimulation is sufficient to cause T cell proliferation (Meuer and Meyer zum Bueschenfeld, 1986) . After 2 d of PHA treatment, >30% of the leukocytes left the GO phase and entered S phase (Figure 1 ). The levels of telomerase activity in extracts from the untreated and PHA-treated cells were compared ( Figure 1 ). Telomerase activity was measured with a PCR-enhanced telomerase assay in which the enzyme was assayed under optimal conditions (Morin, 1989) , and reaction products were amplified by PCR. A minimal number of PCR amplification cycles was used to minimize the possibility of PCRgenerated artifacts and to insure quantitative results (see MATERIALS AND METHODS). In extracts from the untreated leukocytes, telomerase activity was not detected (Figure 1) . In extracts from cells treated for 1 d with PHA, a low level of activity just above the lower limit of detection of the assay was observed. From day 1 to day 2 there was a >10-fold increase in activity as quantified by phosphorimaging (see MA-TERIALS AND METHODS), and the level of activity remained high in extracts from cells treated for 3 d with PHA. The timing of the increase in telomerase activity correlated with the increase in the percentage of cells in S phase.
To verify that the telomerase activity assayed in the heterogeneous population of leukocytes after PHA treatment resulted from T cells, we tested the ability of antibodies specific for the TCR/CD3 complex to upregulate telomerase activity in a T cell-enriched fraction of leukocytes. In the absence of antigen-presenting cells, maximal stimulation of interleukin 2 (IL-2) expression and T cell proliferation requires TCR/CD3 signaling along with a costimulatory signaling pathway (Schwartz, 1992; Shahinian et al., 1993) . Thus, we expected that, if the increase in telomerase activity results from T cells and is dependent on IL-2 expression, both TCR/CD3 and CD28 signaling would be required for maximal telomerase expression.
We isolated a T cell-enriched fraction of leukocytes and cultured the cells in the presence of anti-TCR/CD3 and/or anti-CD28 antibodies. After 2 d of culturing in the presence of one or both antibodies, the cells were harvested and analyzed for telomerase activity (Figure 2 ). Telomerase activity was not observed in the control (media alone), anti-TCR/ CD3, or anti-CD28 samples. However, telomerase activity was detected in the sample treated with both anti-TCR/CD3 and anti-CD28. Thus, telomerase was activated by the T cell-specific TCR/CD3 and CD28 signaling pathways. In this experiment, telomerase activation required both TCR/CD3 signaling and CD28 signaling (Figure 2 ). In a second experiment, a low level of telomerase activity was detected with anti-TCR/CD3 alone, no activity was detected with anti-CD28 alone, and a high level of activity was detected with anti-TCR/CD3 and anti-CD28 in combination (our unpublished results). In both experiments, maximal telomerase activation required both TCR/ CD3 and CD28 signaling, as does maximal IL-2 expression and proliferation in T cells (Schwartz, 1992; Shahinian et al., 1993) . The requirement for both TCR/ CD3 and CD28 signaling to achieve maximal telomerase activity is consistent with telomerase induction being downstream of IL-2 signaling. The timing of the increase in telomerase activity after PHA treatment of leukocytes (Figure 1 ) suggested that telomerase activation was a later event than IL-2 and IL-2Ra expression (Ullman et al., 1990) .
To further examine the correlation between cell cycling and telomerase activation, PHA-treated cells were treated with exogenous IL-2 at a concentration that would accelerate cell cycling, the IL-2 and PHA were then depleted to induce proliferative arrest, and the cells were restimulated with PHA. During this regimen of PHA and IL-2 stimulation, depletion, and restimulation ( Figure 3A) , telomerase activity and the percentage of cells in S phase were assayed. Cell number as an indicator of population doubling rates and cellular debris as an indicator of cell death were also monitored. Cells treated with PHA for 3 d had detectable telomerase activity (Figures 1 and 3B ). After the initial 3 d of PHA treatment, cells were treated with IL-2. The cells divided rapidly after IL-2 addition, resulting in three population doublings in 1 d of treatment, an increase in the percentage of cells in S phase, and an increase in telomerase activity (Figure 3, A and  B) . During the next 4 d, IL-2 and PHA were not replenished in the culture, and the population doubling rate declined with only one doubling occurring from day 5 to day 8. By day 8 of the experiment, 98% of the cell population was in GO/Gi phase, and telomerase activity was no longer detected. Restimulation of the cells with PHA resulted in a modest increase in S phase cells and an increase in telomerase activity (Figure 3A) . The magnitude of this increase cannot be compared directly with that seen after PHA stimulation of day 0 leukocytes, because the cellular composition of the population, the activation and differentiation state of the T cells, and the length of PHA treatment are different. This stimulation, depletion, and restimulation experiment demonstrated a correlation between cell-cycle entry and telomerase activation, as well as a correlation between cell-cycle exit and the down-regulation of telomerase activity. In addition, the superinduction of telomerase within 1 d of IL-2 treatment demonstrated telomerase regulation by IL-2 signaling pathways. To determine whether the absence of telomerase activity in untreated leukocytes was due to the presence of an inhibitor of telomerase activity, telomerasenegative (day 0) and telomerase-positive (PHA, day 2) extracts were mixed at different concentrations ( Figure  4 ). An equal amount or up to a ten-fold excess of telomerase-negative extract did not inhibit the activity in telomerase-positive extracts, although some decrease in the longest products was seen. We conclude that the telomerase-negative extracts did not contain a diffusible inhibitor of telomerase activity.
To investigate whether the level of the RNA component of telomerase (human telomerase RNA or hTR; Feng et al., 1995) was regulated in leukocytes, we performed Northern analysis. RNA was isolated from leukocytes that were cultured in the absence or presence of PHA for 2 d. As a positive control, RNA was also isolated from a telomerase-positive (Prowse et al., 1993) , immortal T cell leukemia cell line, Jurkats. The steady-state levels of hTR relative to 5S RNA increased after 2 d of PHA stimulation (Figure 5 ), paralleling the increase in telomerase activity in these cells (Figure 1) .
To investigate telomerase regulation in the pathway(s) downstream of IL-2 receptor and relative to cell-cycle progression, we blocked T cell proliferation with the immunosuppressive drug rapamycin. Rapamycin blocks antigen-induced T cell proliferation downstream of IL-2 receptor and other growth factor receptors including IL-4 and IL-6 (reviewed in Sigal and Dumont, 1992; Morice et al., 1993) . Rapamycin inhibits the elimination of p27K'Pl, an inhibitor of cyclin-dependent kinases, and blocks the activation of the cyclin-dependent kinase 2 (cdk2), a kinase required for the Gl-to-S phase transition (Nourse et al., 1994) . Rapamycin, however, does not block some other IL-2-mediated activities, such as the enhancement of cytolytic function in cytotoxic T cells (Morice et al., 1993) . We tested the ability of rapamycin to inhibit telomerase after PHA and IL-2 treatment. Freshly isolated quiescent leukocytes were treated with PHA and IL-2 in the presence of 5 or 50 nM rapamycin. The cells were harvested 2 d later and analyzed for cell-cycle phase distribution and telomerase activity (Figure 6 ). PHA and IL-2 treatment for 2 d resulted in an increase in S phase cells. Rapamycin treatment blocked both the increase in telomerase activity and the increase in S phase cells to control levels ( Figure 6A ). The effect of rapamycin over a broader concentration range, 0.05-500 nM, was determined ( Figure 6B ). Again, rapamycin inhibited both S phase and telomerase activity.
Rapamycin blocks cells in a Gl-phase-like state Nourse et al., 1994 Leukocytes were treated for 2 d with PHA and IL-2 in the presence of rapamycin or hydroxyurea. The cells were lysed, and extracts were assayed for cdk2 kinase activity in vitro and for steady-state protein levels of cdk2, cyclin E, and p27KiP1 by Western blotting. In agreement with published results (Nourse et al., 1994) , rapamycin-blocked cells had high cyclin E protein levels, low cdk2 kinase activity, and high p27KiPl protein levels (Figure 8 ). Hydroxyurea-treated cells expressed high levels of cyclin E protein, high cdk2 kinase activity, and low p27KiPl protein levels (Figure 8) . These results are consistent with rapamycin inhibiting cells in Gl phase and hydroxyurea blocking cells in early S phase, indicating that telomerase is activated in Gi phase as T cells enter the cell cycle. jig) was run on a 6% acrylamide/7 M urea/0.6X TBE gel, transferred to nylon membrane, and probed with 32P-labeled hTR antisense riboprobe and 32P-labeled 5S RNA probe.
whether an inhibitor of DNA synthesis would have the same effect on telomerase activity, we treated leukocytes with hydroxyurea. Although hydroxyurea did inhibit S phase progression, the induction of telomerase activity was not blocked ( Figure 6C ). This demonstrated that telomerase induction occurred independently of DNA synthesis.
To rule out the possibility that rapamycin directly inhibited telomerase activity, rapamycin was added to a telomerase assay in vitro. Hydroxyurea was also tested for inhibition of telomerase in vitro. At concentrations equivalent to or 10-fold greater than those used in the leukocyte culture medium, neither rapamycin nor hydroxyurea inhibited telomerase activity in vitro (Figure 7) . Thus, the effect of rapamycin on telomerase in vivo is likely to result from the inhibition of IL-2 signaling and of cell-cycle progression.
To examine the cell-cycle phase of the rapamycinand hydroxyurea-blocked leukocytes, we used the cyclin-de1pendent kinase 2 (cdk2), cyclin E, and the p27K'P4 cdk inhibitor as molecular indicators of cellcycle phase progression. Cyclin E expression and cdk2 kinase activity increase gradually in Gl phase and are required for the Gl-to-S phase transition (Pagano et al., 1993; Tsai et al., 1993; van den Heuvel and Harlow, 1993; Ohtsubo et al., 1995) ; p27K'Pl is expressed at high levels in quiescent T cells but at low levels in exponentially proliferating T cells (Nourse et al., 1994) .
DISCUSSION
Although telomerase is not expressed in many somatic tissues, it is expressed in peripheral blood leukocytes (Broccoli et al., 1995; Counter et al., 1995; Hiyama et al., 1995) . These cells provided a normal human cell type in which to study telomerase regulation. PHA treatment of peripheral blood leukocytes (Figure 1 ; Hiyama et al., 1995) or antibody activation of TCR/ CD3 and CD28 receptors (Figure 2 ) resulted in an increase in telomerase activity. Thus, the T cell receptor and CD28 costimulatory pathways are linked to telomerase activation. Telomerase induction after TCR engagement correlated with the progression of T lymphocytes from Gl into S phase.
The signaling events downstream of TCR/CD3 complex that signal the entry into S phase have been well studied. Signals generated from the TCR establish an autocrine signaling pathway involving IL-2 and IL-2 receptor (IL-2R; Ullman et al., 1990; Crabtree and Clipstone, 1994) . Signals from the IL-2R commit the cell to a program of DNA synthesis by communicating with components of the cell-cycle machinery. The signaling pathway is blocked by the immunosuppressant rapamycin, which blocks the phosphorylation of the retinoblastoma protein (RB), the expression of cyclin A and PCNA, the down-regulation of p271TP11, and the activation of p33cdk2 (reviewed in Chou and Blenis, 1995) . We found that rapamycin blocked the induction of telomerase, whereas hydroxyurea did not, indicating that telomerase is regulated in Gl phase. The inability of hydroxyurea to block telomerase activation indicated that telomerase is induced before DNA synthesis and that DNA synthesis itself is not required for telomerase induction.
The increase in telomerase activity after PHA stimulation was accompanied by an increase in the level of the telomerase RNA component. Because the levels of the telomerase RNA component ( Figure  4 ) and telomerase activity (Buchkovich and Greider, Vol. 7, September 1996 ei- ther serum starvation or contact inhibition, the cells arrested in GO after 24 h, yet telomerase activity remained constant relative to the levels in the cycling populations (Buchkovich and Greider, unpublished results) . When similar immortal fibroblast populations were held quiescent only after 7-13 d, some decrease in telomerase activity was seen (Holt et al., 1996) . This suggests that telomerase activity is not tightly regulated with cell-cycle exit in immortal mouse fibroblast lines, or that the enzyme has a long half-life. Differentiation in vitro of a variety of immortal cell types leads to low or undetectable telomerase activity (Sharma et al., 1995; Holt et al., 1996) . The decline in telomerase activity was apparently slower than the decline of cell-cycle-associated activities in some cases. manner. Whether this lack of regulation is due to a relaxed control in immortal cell clones or is also found in normal human cells remains to be demonstrated. The identification of telomerase regulation in normal human T cells by the TCR pathway demonstrates that mature T cells have telomerase activity. Previous experiments with unstimulated leukocytes showed low levels of telomerase activity in both mixed cell population and in fractionated samples containing specific cell types (Broccoli et al., 1995) . This activity may be attributed to the presence of progenitor stem cells in the population Harley, 1995b; Shay and Wright, 1996) . However, peripheral blood T cells responding to TCR agonists are not progenitor hematopoietic cells but, rather, mature T cells that have survived thymic selection (Crabtree, 1989) . The finding that telomerase is expressed in these cells is significant, because earlier data suggested that only -TS+6 -TS+5 1 2 3 4 5 6 7 8 9 10 11 12 13 Figure 7 . Neither rapamycin nor hydroxyurea inhibited telomerase activity in vitro. An extract from PHA-treated leukocytes was assayed for telomerase activity at two protein concentrations: 0.5 jig per reaction (lane 3) or 2.5 ,g per reaction (lanes 1-2 and 4-12). Rapamycin (50,500, or 5000 nM), hydroxyurea (1, 10, or 100 mM), or the solvents used to dissolve rapamycin and hydroxyurea (ethanol and water, respectively) were added to the leukocyte extract before the telomerase assay. Assay controls for PCR efficiency (control; lane 1), RNase-sensitivity (RNase; lane 2), and extract-independent activity (no extract; lane 13) were included. dephosphorylated retinoblastoma protein, a marker of GO/Gl phase cells (Mihara et al., 1989) , 3 d of retinoic acid treatment is insufficient for the downregulation of telomerase activity (Sharma et al., 1995) . Whereas changes in E2F complexes are obvious by 5 d of retinoic acid treatment in F9 cells (La Thangue and Rigby, 1987) , telomerase activity did not decrease even after 6 d (Sharma et al., 1995) . The long periods of time required to see reduction in telomerase in these systems again suggests that either telomerase activity has a long half-life or that the enzyme is not tightly regulated with cell-cycle exit in these cells. The T cell experiments described in this paper addressed only the decisions to enter and exit the cell cycle, not the continued progression of cycling cells into each stage of the cell cycle. Phase-specific cellcycle regulation of telomerase activity was not detected in HeLa (Avilion, 1995) or in two other immortal cell types, HT1080 or HL60 cells (Holt et al., 1996) . In all three cases, similar levels of activity were detected in cells in the Gl, S, and G2/M phases of the cell cycle. Thus, the evidence to date suggests that telomerase activity is not regulated in a phase-dependent The identification of telomerase activation in mature T cells raises questions as to the role of telomerase in these cells. Telomere shortening with aging has been observed in total leukocyte populations, in hematopoietic progenitor cells, and in CD4+ naive and memory cells (Hastie et al., 1990; Lindsey et al., 1991; Vaziri et al., 1993 Vaziri et al., , 1994 Weng et al., 1995) . Although telomere shortening in many primary cell types in vitro has been interpreted as an indicator of the absence of telomerase (Harley, 1990 ; reviewed in Harley, 1991; Hastie et al., 1990; Lindsey et al., 1991) , this may not always be the case. Telomeres shorten with age in hematopoietic progenitor cells (CD34+ CD38 10o), yet telomerase activity is present (Vaziri et al., 1994; Hiyama et al., 1995) . These data and our finding of telomerase activity in mature T cells suggest that the ability to express telomerase may not always lead to telomere length maintenance. There are large numbers of factors that are involved in maintaining telomere length, including telomerase, telomerase regulators, telomere binding proteins, and possibly telomere processing activities (reviewed in Greider, 1996) . If some of these other factors are limiting in human T cells, the expression of telomerase will not be sufficient to maintain telomere length. An example of this is seen in the yeast estl mutant, which fails to maintain telomere length although the cells have levels of telomerase activity indistinguishable from wild-type cells (Lundblad and Szostak, 1989; Cohn and Blackburn, 1995 Igarashi and Sakaguchi (1996) and Weng et al. (1996) also observed telomerase induction after stimulation of the T cell antigen receptor.
